Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept
September 18, 2024 07:30 ET
|
Opthea Limited
Three consecutive commercial-scale batches successfully produced Major milestone for potential BLA filing of sozinibercept in wet AMD Progress update of drug product PPQ campaign expected in...
Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight
September 10, 2024 07:30 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Announces Executive Leadership Changes and Senior Hires
September 05, 2024 06:00 ET
|
Opthea Limited
Daniel Geffken and Mike Campbell respectively appointed CFO ad interim and CCOThree senior leaders appointed for Biometrics, Clinical Operations and Market AccessDeepening retina and launch expertise...
Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference
September 03, 2024 07:30 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Reports Full-Year Financial Results and Business Updates
August 30, 2024 07:30 ET
|
Opthea Limited
Completed patient enrollment in COAST and ShORe pivotal wet AMD trials Financings extended cash runway through topline data readout of both trials in CY2025 Leadership appointments in...
Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024
August 08, 2024 08:10 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board
July 17, 2024 07:15 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer
July 14, 2024 21:46 ET
|
Opthea Limited
New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence normal trading on Thursday, 18 July 2024 Retail Entitlement Offer follows...
Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD
July 09, 2024 07:30 ET
|
Opthea Limited
Research underpins sozinibercept’s potential as novel, first-in-class VEGF-C/D ‘trap’ to prevent blood vessel growth and vascular leakage in the retina Published in peer-reviewed journal...
Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens
June 18, 2024 20:57 ET
|
Opthea Limited
Fully underwritten Retail Entitlement Offer to open at 9:00 am (Melbourne time) on 19 June 2024 Retail Entitlement Offer to raise approximately A$55.0m (US$36.9m1) will close at 5:00 pm...